Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH

Phase 1 clinical data poster selected as a Best of EASL 2026 presentation

Combination of denifanstat and resmetirom was generally well-tolerated in Phase 1 clinical trial

Phase 1 data show rapid reductions in cholesterol levels, suggesting the potential for a cardiovascular benefit

SAN MATEO, Calif., May 27, 2026 (GLOBE NEWSWIRE) --  Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the presentation of two posters at the European Association for the Study of the Liver (EASL) Annual Congress 2026, being held in Barcelona, Spain on May 27-30, 2026. The Late-Breaking denifanstat/resmetirom poster, covering Phase 1 clinical data on the combination of Sagimet's oral once-daily fatty acid synthase (FASN) inhibitor, denifanstat, and resmetirom, a thyroid hormone receptor beta (THR-β) agonist, was selected as a Best of EASL 2026 presentation. A second poster presents preclinical data on the combination's mechanism of action.

EASL Poster Presentation Details:

Selected for Best of EASL 2026: Denifanstat and resmetirom combination therapy rapidly decreased atherogenic lipids in healthy adults in Phase 1 open-label trial 

• Presenter: Mary E. Rinella, MD, University of Chicago
• Session: LBP-032
• Date: Wednesday to Saturday, May 27-30, 2026
• Author attending: Friday, May 29th 12:45 to 1:45 PM CEST
• Location: Fira Barcelona, Spain

Poster Highlights:

This Phase 1 trial built on preclinical data showing that the combination of a FASN inhibitor and resmetirom improved liver histology versus monotherapy through complementary mechanisms of liver fat reduction and denifanstat’s direct anti-fibrotic effect.

The Phase 1 open label clinical trial evaluated the safety, pharmacodynamics, and pharmacokinetics of the denifanstat/resmetirom combination in 40 healthy adults with a mean BMI of 30-32 kg/m2. Two cohorts assessed different dosing sequences: subjects received 7 days of monotherapy followed by 7 days of combination therapy. Cohort 1 initiated monotherapy with denifanstat and Cohort 2 with resmetirom. Denifanstat was dosed at 50 mg and resmetirom utilized weight-based dosing (80 or 100 mg).

Topline safety data reported in December 2025 showed that the combination of denifanstat and resmetirom was generally well-tolerated over the duration of the study, with no safety signals. Clinical data reported for the first time at EASL 2026 show rapid reduction in total and LDL cholesterol levels (p